Scarica l'app Stockscreener
3.50
7.16%
-0.27
Ironwood Pharmaceuticals Inc Borsa (IRWD) Ultime notizie
Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3? - Zacks Investment Research
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential? - Zacks Investment Research
Form 144 IRONWOOD PHARMACEUTICALS INC For: 27 September By Investing.com - Investing.com Australia
Form 144 IRONWOOD PHARMACEUTICALS INC For: 27 September By Investing.com - Investing.com Nigeria
Form 144 IRONWOOD PHARMACEUTICALS INC For: 27 September By Investing.com - Investing.com India
83,306 shares to cover taxes: Ironwood Pharmaceuticals (IRWD) ex-officer proposes a sale - Stock Titan
Ironwood Pharmaceuticals Director Alexander J. Denner Awarded 3,694 Shares Under Compensation Policy - Kalkine Media
Ironwood: Medicare Is Not The Problem I Thought It Was - Seeking Alpha
Ironwood Pharmaceuticals at Wells Fargo conference: linzess rebound drives turnaround - Investing.com Canada
Ironwood Pharmaceuticals at Wells Fargo conference: linzess rebound drives turnaround - Investing.com UK
IRWD Stock Price, Quote & News - Syfe
IRWD stock gains as Wells Fargo conference spotlight shifts to cash flow - ad-hoc-news.de
Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference - Yahoo Finance
Ironwood Pharmaceuticals Inc. Class A (IRWD) Peer Comparison – Compare with Others - Value Research
Ironwood Pharmaceuticals (IRWD) Slips 2.6% as Shares Approach Key Support at $3.92Backspread Trade - vinanet.vn
Ironwood Pharmaceuticals (IRWD) Slips 2.59% to $4.13: Analyzing Key Support and Resistance LevelsETF Flow - dars.gov.et
Ironwood Pharmaceuticals Inc. Class A (IRWD) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Ironwood Pharmaceuticals: High Dependence On Its Next Trial (NASDAQ:IRWD) - Seeking Alpha
Ironwood (IRWD) Results Versus Estimates: EPS Does Not Reach the Reported Estimate for the Current Session; Market Move: The Market Price Moves 1.16% Higher in Latest TradingEarnings Yield Analysis - vinanet.vn
Ironwood Pharmaceuticals (IRWD) Edges Higher: Shares Advance 1.16% as Bulls Defend Key SupportRSI Oversold Picks - vinanet.vn
Ironwood Pharmaceuticals (IRWD) Edges Higher: Shares Advance 1.16% as Bulls Defend Key SupportValue ETF - dars.gov.et
Jeffrey Silber Net Worth (2026) - GuruFocus
Bank of America Corp DE Sells 2,838,753 Shares of Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Ironwood Pharmaceuticals | ARS: Annual Report to Security Holders - Moomoo
Ironwood Pharmaceuticals (IRWD) Q2 2026 Earnings: EPS Misses Estimates, Stock Climbs 5.64%Dividend Growth Analysis - vinanet.vn
Armistice Capital (IRWD) discloses 13.9M-share Ironwood Pharmaceuticals stake - stocktitan.net
Dimensional Fund Advisors LP Raises Holdings in Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Gap DownTime to Sell? - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Posts Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Ironwood Pharmaceuticals, Inc. $IRWD Shares Sold by Amundi - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Downgraded to Buy Rating by Wall Street Zen - MarketBeat
State Street Corporation (NYSE: IRWD caretaker) holds 5.4% of Ironwood common stock - Stock Titan
Ironwood Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Pacer Advisors Inc. Makes New $3.98 Million Investment in Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View Raised - Eastern Progress
Ironwood Pharmaceuticals Inc (IRWD) (Q2 2026) Earnings Call High - GuruFocus
Ironwood Pharmaceuticals (IRWD) Is Up 14.2% After Raising 2026 Revenue Guidance – Has The Bull Case Changed? - Yahoo! Finance Canada
Ironwood Pharmaceuticals Inc (IRWD) (Q2 2026) Earnings Call Highlights: Strong LINZESS Growth ... - Yahoo Finance
IRWD Looks 15.8% Undervalued on GF Value™ as Debt Reduction Effo - GuruFocus
Ironwood Pharmaceuticals Q2 Earnings Call Highlights - Yahoo Finance
Ironwood Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:IRWD) 2026-08-06 - Seeking Alpha
Is Ironwood Pharmaceuticals (IRWD) Undervalued After Q2 Earnings - GuruFocus
IRWD: LINZESS sales surged and guidance was raised as apraglutide advanced in phase III trials - TradingView
Ironwood Pharmaceuticals (IRWD) Q2 Earnings Top Estimates - Yahoo Finance
Ironwood Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Ironwood Raises 2026 Guidance After Q2 Revenue Hits $113 Million - Quiver Quantitative
BRIEF-Ironwood Pharmaceuticals Q2 Revenue USD 113.041 Million Vs. IBES Estimate USD 114.8 Million - TradingView
Press Release: Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results - Moomoo
Segall Bryant & Hamill LLC Buys New Position in Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Lazard Asset Management LLC Sells 710,256 Shares of Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
2.82%
0.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):